The short version
18 companies supply this market — deep enough that no single failure threatens the supply. The price has fallen 42% in a year, to $0.0796 per mL — and generics that get this cheap tend to get abandoned rather than defended. It is in shortage right now — FDA lists the reason as “demand increase for the drug”.